Houston-based biotechnology company FibroBiologics, Inc. (Nasdaq: FBLG) released its second quarter financial results for 2025 and provided a corporate update. The company, which specializes in developing therapeutics and potential cures for chronic diseases through the use of fibroblasts and fibroblast-derived materials, currently holds over 275 patents that are either issued or pending. FibroBiologics shared important information about its progress but did not disclose specific details.